Viability of a Drug-Resistant Human Immunodeficiency Virus Type 1 Protease Variant: Structural Insights for Better Antiviral Therapy

Under the selective pressure of protease inhibitor therapy, patients infected with human immunodeficiency virus (HIV) often develop drug-resistant HIV strains. One of the first drug-resistant mutations to arise in the protease, particularly in patients receiving indinavir or ritonavir treatment, is...

ver descrição completa

Detalhes bibliográficos

Publicado no:	J Virol
Principais autores:	Prabu-Jeyabalan, Moses, Nalivaika, Ellen A., King, Nancy M., Schiffer, Celia A.
Formato:	Artigo
Idioma:	Inglês
Publicado em:	American Society for Microbiology (ASM) 2003
Assuntos:	Vaccines and Antiviral Agents
Acesso em linha:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC140781/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/12502847/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/JVI.77.2.1306-1315.2003
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!